Search

Fragestellung/Einleitung: Prüfungsvorbereitende, veranstaltungsbegleitende sowie fächerübergreifende Tutorien im Sinne des peer-teaching[ref:1] werden von der LMU Co.Med seit dem Wintersemester 2008/09 vorwiegend für Studierende im ersten Studienabschnitt (Vorklinik)[zum vollständigen Text gelangen Sie über die oben angegebene URL], Gemeinsame Jahrestagung der Gesellschaft für Medizinische Ausbildung (GMA) und des Arbeitskreises zur Weiterentwicklung der Lehre in der Zahnmedizin (AKWLZ)

Edmund Schütz, “Remarks on Initial D- in Kipchak Languages”, Acta Orientalia Scientiarum Hungaricae, Tomus XXV, 1972, 369-381. ** Arş. Gör., Gazi Üniversitesi, Edebiyat Fakültesi, Türk Dili ve Edebiyatı Bölümü. musasalan@yahoo.com, 1 PhTF I, 378. 2 a.g.e., 350. 3 a.g.e., 413. 4 a.g.e., 426. 5 Grammatika baškirskogo jazyka, 1943, 30. 6 PhTF I, 396. 7 Qaraqalpaq Grammar, 1947, 33-36; CAJ I, 114, 120, IV, 99. 8 PhTF I, 451. 9 The Turkic Languages and Peoples (Ural-Alt. Bibl. XV), 86. Şimdilik bu merak uyandırıcı teori hakkında daha fazla detay vermek istemiyorum

Einleitung: Seit dem Wintersemester 2008/09 leiten Studierende der Medizin Veranstaltungen im Sinne des peer-teaching[ref:1] an der LMU. Im Fokus steht dabei die Ergänzung und Unterstützung der Lehre im vorklinischen Studienabschnitt. Die eigenständige inhaltliche und didaktische[for full text, please go to the a.m. URL], Jahrestagung der Gesellschaft für Medizinische Ausbildung (GMA)

Einleitung: Das Curriculum im ersten Studienabschnitt des Medizinstudiums (Vorklinik) der LMU ist für alle Studierende sehr uniform. Individuelle Vorkenntnisse und Lernanforderungen werden kaum berücksichtigt. Seit dem Wintersemester 2008/09 werden Tutorien [ref:1] – [for full text, please go to the a.m. URL], Jahrestagung der Gesellschaft für Medizinische Ausbildung (GMA)

Background Aminosalicylates are used as standard treatment for maintaining remission in ulcerative colitis. As yet, there is no other existing alternative with proven efficacy. In light of the hypothesis that the intestinal environment may contribute to the pathophysiology of ulcerative colitis, a trial was conducted to test the effects of probiotic treatment with an oral preparation of non-pathogenic E. coli. Methods A total of 120 patients with inactive ulcerative colitis were included in a double-blind, double-dummy study comparing mesalazine 500 mg t.d.s. to an oral preparation of viable E. coli strain Nissle (Serotype 06: K5: H1) for 12 weeks with regard to their efficacy in preventing a relapse of the disease. Study objectives were to assess the equivalence of the clinical activity index (CAI) under the two treatment modalities and to compare relapse rates, relapse-free times and global assessment. Results The start and end scores of the CAI demonstrated no significant difference (P=0.12) between the two treatment groups. Relapse rates were 11.3% under mesalazine and 16.0% under E. coli Nissle 1917 (N.S.). Life table analysis showed a relapse-free time of 103±4 days for mesalazine and 106±5 days for E. coli Nissle 1917 (N.S.). Global assessment was similar for both groups. Tolerability to the treatment was excellent and did not differ. No serious adverse events were reported. Conclusions From the results of this preliminary study, probiotic treatment appears to offer another option for maintenance therapy of ulcerative colitis. Additional support is provided for the hypothesis of a pathophysiological role for the intestinal environment in ulcerative colitis.

The effect of a prokinetic agent, cisapride, on the relapse of reflux esophagitis was investigated in a randomized, double-blind trial conducted in 443 patients whose esophagitis had previously been healed with an acid antisecretory drug. Patients received cisapride, 20 mg at night, cisapride 10 mg twice daily, or placebo for 12 months or until endoscopic relapse was confirmed endoscopically. In 88% of all patients (respectively 133, 132, and 124), endoscopic data were available at discontinuation of treatment. In comparison with placebo, the two cisapride regimens prolonged both the time to endoscopically confirmed relapse (Kaplan-Meier analysis;P=0.001) and the time to symptomatic relapse (P=0.012). The life-table endoscopic relapse rates at 12 months were 51% for placebo, 32% for cisapride 20 mg at night (P=0.005), and 34% for cisapride 10 mg twice daily (P=0.02). Patients with more severe esophagitis before healing relapsed more rapidly during maintenance therapy, regardless of the treatment regimen. Adverse events were infrequent in all three groups. These findings indicate that maintenance treatment with the prokinetic drug cisapride prevents the relapse of esophagitis after it has been healed by acid antisecretory therapy.